Oct. 17, 2019: Tesamorelin as treatment for non-alcoholic fatty liver disease; reversing lipid changes via TDF => TAF => TDF; statin use and reduced chronic kidney disease risk; statin use and (no) reduced HIV persistence.
A series of studies aim to determine whether test-and-treat strategies can be implemented for people with hepatitis C, much like programs for people living with HIV.
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
Steven Deeks, M.D., talks about the medical community's hopes, inspirations, and unanswered questions regarding research for an HIV cure.
Although several HCV drugs can cure almost all infections regardless of viral genotype, picking the right drug will depend on each patient's medical history, level of liver damage, and coinfections.
July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.
Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.
Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.